Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 17 (8)

Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia


Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia

Letteria Minutoli et al. Int J Mol Sci.


Benign prostatic hyperplasia (BPH) is a chronic condition common in older men that can result in bothersome lower urinary tract symptoms. The molecular mechanisms and networks underlying the development and the progression of the disease are still far from being fully understood. BPH results from smooth muscle cell and epithelial cell proliferation, primarily within the transition zone of the prostate. Apoptosis and inflammation play important roles in the control of cell growth and in the maintenance of tissue homeostasis. Disturbances in molecular mechanisms of apoptosis machinery have been linked to BPH. Increased levels of the glycoprotein Dickkopf-related protein 3 in BPH cause an inhibition of the apoptosis machinery through a reduction in B cell lymphoma (Bcl)-2 associated X protein (Bax) expression. Inhibitors of apoptosis proteins influence cell death by direct inhibition of caspases and modulation of the transcription factor nuclear factor-κB. Current pharmacotherapy targets either the static component of BPH, including finasteride and dutasteride, or the dynamic component of BPH, including α-adrenoceptor antagonists such as tamsulosin and alfuzosin. Both these classes of drugs significantly interfere with the apoptosis machinery. Furthermore, phytotherapic supplements and new drugs may also modulate several molecular steps of apoptosis.

Keywords: apoptosis; benign prostatic hyperplasia; treatment.


Figure 1
Figure 1
Schematic representation of the endocrine-linked apoptotic mechanisms involved in benign prostatic hyperplasia (BPH) and of its medical treatments.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles


    1. Kirby R.S. The natural history of benign prostatic hyperplasia: What have we learned in the last decade? Urology. 2000;56:3–6. doi: 10.1016/S0090-4295(00)00747-0. - DOI - PubMed
    1. Emberton M., Fitzpatrick J.M., Garcia-Losa M., Qizilbash N., Djavan B. Progression of benign prostatic hyperplasia: Systematic review of the placebo arms of clinical trials. Br. J. Urol. 2008;102:981–986. doi: 10.1111/j.1464-410X.2008.07717.x. - DOI - PubMed
    1. Speakman M., Kirby R., Doyle S., Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)—Focus on the UK. Br. J. Urol. 2014;115:508–519. doi: 10.1111/bju.12745. - DOI - PubMed
    1. Saigal C.S., Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J. Urol. 2005;173:1309–1313. doi: 10.1097/01.ju.0000152318.79184.6f. - DOI - PubMed
    1. Vuichoud C., Loughlin K.R. Benign prostatic hyperplasia: Epidemiology, economics and evaluation. Can. J. Urol. 2015;22:1–6. - PubMed